Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.62 |
| ▸ | IGF1R | P08069 | 9/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | SGK1 | O00141 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8298163 | 0.92 | CAMKK2 (0.64) | CAMKK2IGF1RAAK1RIPK1AXL | |
| SCHEMBL15161540 | 0.91 | CAMKK2 (0.61) | CAMKK2IGF1RAAK1RIPK1SGK1 | |
| SCHEMBL14499651 | 0.88 | CAMKK2 (0.57) | CAMKK2IGF1RAAK1 | |
| SCHEMBL4194938 | 0.86 | CAMKK2 (0.55) | CAMKK2IGF1RAAK1 | |
| SCHEMBL4199507 | 0.82 | CAMKK2 (0.61) | CAMKK2IGF1RAAK1AXL | |
| SCHEMBL8255005 | 0.81 | CAMKK2 (0.74) | CAMKK2IGF1RAAK1SGK1AXL | |
| SCHEMBL14524974 | 0.79 | AXL (0.69) | CAMKK2IGF1RAAK1RIPK1SGK1 | |
| SCHEMBL1487600 | 0.77 | CAMKK2 (0.79) | CAMKK2IGF1RAAK1AXL | |
| SCHEMBL13745445 | 0.76 | CAMKK2 (1.00) | CAMKK2IGF1RSGK1AXL | |
| SCHEMBL1487961 | 0.76 | CAMKK2 (0.67) | CAMKK2IGF1RAAK1SGK1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | CAMKK2 260/4885IGF1R 107/4885AAK1 521/4885 |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | MAPK9, IAPP, RNASE1 | CAMKK2 260/4885IGF1R 107/4885AAK1 521/4885 |
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | API5, MAP3K5, MAP3K7 | CAMKK2 83/4885IGF1R 1633/4885AAK1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.